134 related articles for article (PubMed ID: 38423231)
1. A novel mitochondria-targeting DHODH inhibitor induces robust ferroptosis and alleviates immune suppression.
Hai Y; Fan R; Zhao T; Lin R; Zhuang J; Deng A; Meng S; Hou Z; Wei G
Pharmacol Res; 2024 Apr; 202():107115. PubMed ID: 38423231
[TBL] [Abstract][Full Text] [Related]
2. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer.
Mao C; Liu X; Zhang Y; Lei G; Yan Y; Lee H; Koppula P; Wu S; Zhuang L; Fang B; Poyurovsky MV; Olszewski K; Gan B
Nature; 2021 May; 593(7860):586-590. PubMed ID: 33981038
[TBL] [Abstract][Full Text] [Related]
3. The Warburg effect modulates DHODH role in ferroptosis: a review.
Amos A; Amos A; Wu L; Xia H
Cell Commun Signal; 2023 May; 21(1):100. PubMed ID: 37147673
[TBL] [Abstract][Full Text] [Related]
4. Manganese induces tumor cell ferroptosis through type-I IFN dependent inhibition of mitochondrial dihydroorotate dehydrogenase.
Zhang S; Kang L; Dai X; Chen J; Chen Z; Wang M; Jiang H; Wang X; Bu S; Liu X; Zhang G; Tang H
Free Radic Biol Med; 2022 Nov; 193(Pt 1):202-212. PubMed ID: 36228830
[TBL] [Abstract][Full Text] [Related]
5. Depletion of SOD2 enhances nasopharyngeal carcinoma cell radiosensitivity via ferroptosis induction modulated by DHODH inhibition.
Amos A; Jiang N; Zong D; Gu J; Zhou J; Yin L; He X; Xu Y; Wu L
BMC Cancer; 2023 Feb; 23(1):117. PubMed ID: 36737723
[TBL] [Abstract][Full Text] [Related]
6. Dihydroorotate Dehydrogenase Inhibitors Promote Cell Cycle Arrest and Disrupt Mitochondria Bioenergetics in Ramos Cells.
Kadir MFA; Othman S; Nellore K
Curr Pharm Biotechnol; 2020; 21(15):1654-1665. PubMed ID: 32525770
[TBL] [Abstract][Full Text] [Related]
7. Dihydroorotate dehydrogenase (DHODH) inhibitors affect ATP depletion, endogenous ROS and mediate S-phase arrest in breast cancer cells.
Mohamad Fairus AK; Choudhary B; Hosahalli S; Kavitha N; Shatrah O
Biochimie; 2017 Apr; 135():154-163. PubMed ID: 28196676
[TBL] [Abstract][Full Text] [Related]
8. ENT1 blockade by CNX-774 overcomes resistance to DHODH inhibition in pancreatic cancer.
Mullen NJ; Thakur R; Shukla SK; Chaika NV; Kollala SS; Wang D; He C; Fujii Y; Sharma S; Mulder SE; Sykes DB; Singh PK
Cancer Lett; 2023 Jan; 552():215981. PubMed ID: 36341997
[TBL] [Abstract][Full Text] [Related]
9. Development of a biomarker to monitor target engagement after treatment with dihydroorotate dehydrogenase inhibitors.
Pontikos MA; Leija C; Zhao Z; Wang X; Kilgore J; Tornesi B; Adenmatten N; Phillips MA; Williams NS
Biochem Pharmacol; 2022 Oct; 204():115237. PubMed ID: 36055381
[TBL] [Abstract][Full Text] [Related]
10. Functional expression of human dihydroorotate dehydrogenase (DHODH) in pyr4 mutants of ustilago maydis allows target validation of DHODH inhibitors in vivo.
Zameitat E; Freymark G; Dietz CD; Löffler M; Bölker M
Appl Environ Microbiol; 2007 May; 73(10):3371-9. PubMed ID: 17369345
[TBL] [Abstract][Full Text] [Related]
11. Dihydroorotate dehydrogenase regulates ferroptosis in neurons after spinal cord injury via the P53-ALOX15 signaling pathway.
Li D; Lu X; Xu G; Liu S; Gong Z; Lu F; Xia X; Jiang J; Wang H; Zou F; Ma X
CNS Neurosci Ther; 2023 Jul; 29(7):1923-1939. PubMed ID: 36942513
[TBL] [Abstract][Full Text] [Related]
12. Lysyl oxidase-like 3 restrains mitochondrial ferroptosis to promote liver cancer chemoresistance by stabilizing dihydroorotate dehydrogenase.
Zhan M; Ding Y; Huang S; Liu Y; Xiao J; Yu H; Lu L; Wang X
Nat Commun; 2023 May; 14(1):3123. PubMed ID: 37253718
[TBL] [Abstract][Full Text] [Related]
13. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors.
Vyas VK; Ghate M
Mini Rev Med Chem; 2011 Oct; 11(12):1039-55. PubMed ID: 21861807
[TBL] [Abstract][Full Text] [Related]
14. Mitochondria-Targeted Prodrug Nanoassemblies for Efficient Ferroptosis-Based Therapy via Devastating Ferroptosis Defense Systems.
Liu N; Lin Q; Huang Z; Liu C; Qin J; Yu Y; Chen W; Zhang J; Jiang M; Gao X; Huo S; Zhu X
ACS Nano; 2024 Mar; 18(11):7945-7958. PubMed ID: 38452275
[TBL] [Abstract][Full Text] [Related]
15. A carboxylic acid isostere screen of the DHODH inhibitor Brequinar.
DeRatt LG; Christine Pietsch E; Tanner A; Shaffer P; Jacoby E; Wang W; Kazmi F; Zhang X; Attar RM; Edwards JP; Kuduk SD
Bioorg Med Chem Lett; 2020 Nov; 30(22):127589. PubMed ID: 33007394
[TBL] [Abstract][Full Text] [Related]
16. Investigating dihydroorotate dehydrogenase inhibitor mediated mitochondrial dysfunction in hepatic in vitro models.
Jones SW; Penman SL; French NS; Park BK; Chadwick AE
Toxicol In Vitro; 2021 Apr; 72():105096. PubMed ID: 33460737
[TBL] [Abstract][Full Text] [Related]
17. Natural product piperine alleviates experimental allergic encephalomyelitis in mice by targeting dihydroorotate dehydrogenase.
Liu Z; Hu Q; Wang W; Lu S; Wu D; Ze S; He J; Huang Y; Chen W; Xu Y; Lu W; Huang J
Biochem Pharmacol; 2020 Jul; 177():114000. PubMed ID: 32353424
[TBL] [Abstract][Full Text] [Related]
18. DHODH Inhibition Exerts Synergistic Therapeutic Effect with Cisplatin to Induce Ferroptosis in Cervical Cancer through Regulating mTOR Pathway.
Jiang M; Song Y; Liu H; Jin Y; Li R; Zhu X
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672495
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive drug repurposing study for COVID19 treatment: novel putative dihydroorotate dehydrogenase inhibitors show association to serotonin-dopamine receptors.
Berber B; Doluca O
Brief Bioinform; 2021 Mar; 22(2):1023-1037. PubMed ID: 33406218
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial-targeted brequinar liposome boosted mitochondrial-related ferroptosis for promoting checkpoint blockade immunotherapy in bladder cancer.
Ding Q; Tang W; Li X; Ding Y; Chen X; Cao W; Wang X; Mo W; Su Z; Zhang Q; Guo H
J Control Release; 2023 Nov; 363():221-234. PubMed ID: 37717657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
